(Q46394444)

English

Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes (English)

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

0 references

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

Leishmania infantum

1 reference

based on heuristic

inferred from title

author name string

Jean-Loup Lemesre

1

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

Philippe Holzmuller

2

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

Mireille Cavaleyra

3

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

Rachel Bras Gonçalves

4

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

Grégory Hottin

5

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

Gérard Papierok

6

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

language of work or name

0 references

publication date

1 April 2005

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

23

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

22

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

2825-2840

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

Leishmania spp: completely defined medium without serum and macromolecules (CDM/LP) for the continuous in vitro cultivation of infective promastigote forms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Studies on the control of visceral leishmaniasis: validation of the Falcon assay screening test--enzyme-linked immunosorbent assay (FAST-ELISA) for field diagnosis of canine visceral leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

A cross-sectional serodiagnostic survey of canine leishmaniasis due to Leishmania chagasi.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Studies on canine leishmaniasis control. 2. Effectiveness of control measures against canine leishmaniasis in the Isle of Elba, Italy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of eliminating seropositive canines on the transmission of visceral leishmaniasis in Brazil

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Decreased sensitivity to meglumine antimoniate (Glucantime) ofLeishmania infantumisolated from dogs after several courses of drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Immunology of leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

The Ibizian hound presents a predominantly cellular immune response against natural Leishmania infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

The immune response to Leishmania: mechanisms of parasite control and evasion.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Induction of Th1 and Th2 CD4+ subsets during murine Leishmania major infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Regulation of protective immunity against Leishmania major in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

TH1 and TH2 cell antigen receptors in experimental leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Epidermal immunocompetence in canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Early suppression of lymphoproliferative response in dogs with natural infection by Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Analysis of immune responses in dogs with canine visceral leishmaniasis before, and after, drug treatment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Vaccination trial against canine visceral leishmaniasis. Phocean Veterinary Study Group on Visceral Leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Measurement of antigen specific lymphocyte proliferation using 5-bromo-deoxyuridine incorporation. An easy and low cost alternative to radioactive thymidine incorporation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Experiences with vaccines against cutaneous leishmaniasis: of men and mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Specific IgG1 and IgG2 antibody and lymphocyte subset levels in naturally Leishmania infantum-infected treated and untreated dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Vaccines against leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Follow-up study of a vaccination programme against cutaneous leishmaniasis. I. Vaccination with a 5 year-old human strain of L. tropica from the Negev

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Follow-up study of a vaccination programme against cutaneous leishmaniasis. II. Vaccination with a recently isolated strain of L. tropica from Jericho

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

A highly sensitive and rapid procedure for direct PCR detection of Leishmania infantum within human peripheral blood mononuclear cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Canine leishmaniasis: epidemiological risk and the experimental model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Indirect xenodiagnosis of visceral leishmaniasis in 10 HIV-infected patients using colonized Phlebotomus perniciosus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Visceral leishmaniasis in Teresina, State of Piauí, Brazil: preliminary observations on the detection and transmissibility of canine and sandfly infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Leishmaniasis: current status of vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Specific IgG1 and IgG2 antibody responses of dogs to Leishmania infantum and other parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

TheLeishmaniapromastigote surface antigen-2 (PSA-2) is specifically recognised by Th1 cells in humans with naturally acquired immunity toL. major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Dichotomy of the T cell response to Leishmania antigens in patients suffering from cutaneous leishmaniasis; absence or scarcity of Th1 activity is associated with severe infections.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Dichotomy of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Interferon-gamma and interleukin-4 in human Leishmania donovani infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

based on heuristic

inferred from DOI database lookup

Compensation for decreased expression of B7 molecules on Leishmania infantum-infected canine macrophages results in restoration of parasite-specific T-cell proliferation and gamma interferon production.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

based on heuristic

inferred from DOI database lookup

Control of Leishmania infantum infection is associated with CD8(+) and gamma interferon- and interleukin-5-producing CD4(+) antigen-specific T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.11.061

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2004.11.061

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

1 reference

Europe PubMed Central

21 December 2017

http://europepmc.org/abstract/MED/15780731

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46394444&oldid=2109251295"